Insight: 2026 May See a "Crypto Winter," but Institutionalization and On-chain Transformation are Accelerating
BlockBeats News, December 29th, Cantor Fitzgerald pointed out in its latest year-end report that Bitcoin may be entering a prolonged multi-month downward cycle, with the market possibly stepping into an early "crypto winter" in 2026. Analyst Brett Knoblauch believes that Bitcoin has fallen back from this cycle's peak for about 85 days, and the price may continue to be under pressure, even testing the Strategy's average cost line around $75,000.
However, unlike previous cycles, this downward cycle is unlikely to be accompanied by a large-scale liquidation or systemic collapse. Cantor notes that the current market is dominated by institutions rather than retail investors, and the "divergence" between token price performance and on-chain fundamentals is widening, especially in the DeFi, tokenized assets, and crypto infrastructure sectors.
On the regulatory front, the passage of the U.S. "Digital Asset Market Structure Clarity Act" is seen as a key turning point, expected to reduce policy uncertainty and drive banks and asset management institutions to more deeply engage in the crypto market.
Cantor concluded that although 2026 may not usher in a new bull market, the institutionalization of the crypto industry, compliance pathways, and on-chain infrastructure are gradually solidifying while the price cools down.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Analyst Gu Jingci: Follow the trend and adapt flexibly
XRP Ledger adds account control feature, enabling enterprises to manage assets offline.
BUZZ - Goldman Sachs says the price cap on cancer drugs has limited impact on Indian hospitals
October 9 – Goldman Sachs pointed out that India's implementation of a 30% profit margin cap on non-scheduled anticancer drugs (link) will have limited impact on hospitals. The report states that, based on preliminary discussions with hospital chain groups, such drugs account for less than 5% of hospital revenue and 2% to 2.5% of operating profit. The report adds that hospitals can offset the losses by slightly adjusting service charges, such as administration fees. According to a government notice, an expert committee will finalize the list of drugs to be brought under regulation. Driven by the anticipated price cap, the share prices of Max Healthcare MAXE.NS, Apollo Hospitals APLH.NS, and Fortis Healthcare FOHE.NS rose by 1.6% to 2.5%. Previously, since September 30, these stocks had collectively declined by 11% to 11.5%. Year-to-date, FOHE and MAXE are down 11.7% and 14.8%, respectively, while APLH has risen by 11%. (To assist non-English speakers, Reuters provides automated translations of its reports into several other languages. Due to potential errors or missing context in automated translations, Reuters does not guarantee the accuracy of automatic translation texts and offers them solely for readers’ convenience. Reuters accepts no responsibility for any damage or loss caused by using these automated translation features.)
Adding insult to injury! Japanese electronics giant Nidec downgraded by UBS, stock price plunges over 9% and approaches an 11-month low
UBS has downgraded Nidec's rating from "Buy" to "Neutral" and lowered its target price from 2,800 yen to 2,400 yen, citing a more challenging market environment.
Crypto prices
More
